https://pharminent.com/lillys-retatrutide-hits-22-6-weight-loss-in-phase-3-but-cardiovascular-benefit-remains-elusive/ 2026-07-23T20:51:31Z Pharminent en Lilly's Retatrutide Hits 22.6% Weight Loss in Phase 3, But Cardiovascular Benefit Remains Elusive 2026-07-23T20:09:34Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-23-2026/ 2026-07-23T16:35:47Z Pharminent en Strategic News Watch • July 23, 2026 2026-07-23T16:35:45Z Blog https://pharminent.com/lilly-plans-q1-2027-filing-for-obesity-triple-retatrutide/ 2026-07-23T20:03:28Z Pharminent en Lilly plans Q1 2027 filing for obesity triple retatrutide 2026-07-23T12:38:01Z Blog https://pharminent.com/gsks-10-6b-nuvalent-bet-pays-off-early-as-fda-approves-lung-cancer-drug/ 2026-07-23T20:03:44Z Pharminent en GSK's $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug 2026-07-23T11:59:20Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-july-22-2026/ 2026-07-22T21:26:23Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • July 22, 2026 2026-07-22T21:26:21Z Blog https://pharminent.com/arrowheads-plozasiran-cuts-triglycerides-roughly-80-in-two-phase-3-trials/ 2026-07-22T20:17:25Z Pharminent en Arrowhead's Plozasiran Cuts Triglycerides Roughly 80% in Two Phase 3 Trials 2026-07-22T20:17:25Z Blog https://pharminent.com/trump-threatens-100-200-tariffs-on-imported-generic-drugs/ 2026-07-22T20:17:23Z Pharminent en Trump Threatens 100%–200% Tariffs on Imported Generic Drugs 2026-07-22T20:17:23Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-july-22-2026/ 2026-07-22T20:01:52Z Pharminent en Manufacturing Intelligence • Weekly Digest • July 22, 2026 2026-07-22T20:01:50Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-22-2026/ 2026-07-22T19:00:08Z Pharminent en Strategic News Watch • July 22, 2026 2026-07-22T15:59:06Z Blog https://pharminent.com/samsung-biologics-geographic-diversification-is-a-sound-business-decision/ 2026-07-23T13:03:27Z Pharminent en Samsung Biologics: geographic diversification is a sound business decision 2026-07-22T14:12:20Z Blog https://pharminent.com/repligen-builds-in-cell-therapy-with-1-5bn-biolife-takeover/ 2026-07-22T19:05:06Z Pharminent en Repligen builds in cell therapy with $1.5bn BioLife takeover 2026-07-22T13:28:08Z Blog https://pharminent.com/us-generic-tariff-reprieve-on-the-rocks-as-trump-proposes-100-rate-in-2028/ 2026-07-22T19:08:14Z Pharminent en US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 2026-07-22T10:41:55Z Blog https://pharminent.com/novo-nordisk-sues-eli-lilly-over-deceptive-glp-1-advertising/ 2026-07-21T20:53:07Z Pharminent en Novo Nordisk Sues Eli Lilly Over 'Deceptive' GLP-1 Advertising 2026-07-21T20:51:21Z Blog https://pharminent.com/novartis-ends-adc-holdout-with-up-to-1-5b-myricx-bio-deal/ 2026-07-21T20:51:18Z Pharminent en Novartis Ends ADC Holdout With Up-to-$1.5B Myricx Bio Deal 2026-07-21T20:51:18Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-21-2026/ 2026-07-21T20:43:41Z Pharminent en Oncology Intelligence Digest • July 21, 2026 2026-07-21T20:34:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-21-2026/ 2026-07-21T15:49:22Z Pharminent en Strategic News Watch • July 21, 2026 2026-07-21T15:49:20Z Blog